Patients in the lowest quartile of tumor CHD1 expression had a significantly shorter time to progression on either enzalutamide or abiraterone compared with the patients in the highest quartile (p = 0.0261) (Figure 4C), supporting the predictions from the preclinical findings. This evidence concerns the gene CHD1 and neoplasm.